AUSL Rimini
CD4 count at end of HAART interruption influences duration of first interruption
Published in Health Risk Factor Week, April 11th, 2006
Researchers in Italy conducted a study to "evaluate the safety of treatment interruption (TI) guided by CD4+ count in HIV-infected patients followed-up prospectively."
A. Boschi and colleagues at AUSL Rimini explained, "Patients on HAART with a CD4+ cell count >500 cells/mm3 discontinued therapy with instructions to start therapy again before their CD4+ count dropped below 200 cells/mm3. We report data on 112 HIV-infected patients."
"The median follow-up after starting the first TI was 34.7 months...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
More Articles from Health Risk Factor Week
- American College of Cardiology
Researchers find viable new sources for stem cell transplants to the heart - American Society for Aesthetic Plastic Surgery
Venous thromboembolic prophylaxis in plastic surgery stressed to reduce risk of blood clots - Callisto Pharmaceuticals, Inc.
First Berlin issues research update with buy rating on Callisto Pharmaceuticals - Emory University, Atlanta
Mother-adolescent HIV prevention program increases condom use and improves communication - ATS Medical, Inc.
ATS Medical reports first implant of Simulus annuloplasty ring - Aarhus University Hospital
Use of DNA pools to identify single nucleotide polymorphisms linked to colorectal cancer validated - More from this issue of Health Risk Factor Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
